Specifications
- Purity
- ≥98% (HPLC)
- Identity
- 1H-NMR
- Appearance
- White to beige powder
Properties
- Melting Point
- 160.0°C-162.0°C
- Solvents
- DMSO (20mg/ml), DMF (20mg/ml), ethanol (10mg/ml)
Available from stock
Flibanserin
- SKU
- F0337
Category: API's & Intermediates
- Synonyms
- 1,3-Dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one , BIMT 17 , BIMT 17BS
- 167933-07-5
- CAS-Number
- C20H21F3N4O
- Molecular Formula
- 390.40
- Molecular Weight
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at +4°C.
- Long Term Storage
- +4°C
- Short Term Storage
- +4°C
- Shipping
- AMBIENT
- Transportation
- Packing Group III
- RIDADR
- 2811 6.1
- Signal word
- Danger
- GHS Symbol
- GHS06
- Precautionary statements
- P261-P301 + P310-P305 + P351 + P338
- Hazard statements
- H301-H315-H319-H335
- Description
- Flibanserin is a full agonist of the serotonin 5-HT1A receptor and an antagonist of 5-HT2A (Ki=1nm and 49nM, respectively). It also binds to dopamine D4 receptors with Ki values ranging from 4-24 nM, but demonstrates no affinity for the other 5-HT subtypes or other neurotransmitter receptors. Multifunctional serotonergic ligands like flibanserin that can enhance downstream release of dopamine and norepinephrine while concomitantly reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire, are being studied clinically for therapeutic potential to improve sexual functioning. Flibanserin was investigated as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin was also found to reduce L-DOPA-induced dyskinesia in a model of Parkinson?s Disease.
- References
- (1) F. Borsini, et al., Naunyn Schmiedebergs Arch. Pharmacol. 352, 276 (1995) , (2) F. Borsini, et al., Naunyn Schmiedebergs Arch. Pharmacol. 352, 283 (1995) , (3) F. Borsini, et al., Psychopharmacology 134, 378 (1997) , (4) A. Scandroglio, et al., Pharmacol. Res. 43, 179 (2001) , (5) F. Borsini, et al., CNS Drug Rev. 8, 117 (2002) (Review) , (6) R.W. Invernizzi, et al., Br. J. Pharmacol. 139, 1281 (2003) , (7) H. Gelez, et al., J. Sex. Med. 10, 1231 (2013) , (8) S.M. Stahl, CNS Spectr. 20, 1 (2015) (Review) , (9) I. Dhanuka & J.A. Simon, Expert Opin. Pharmacother. 16, 2523 (2015) (Review)
- InChi Key
- PPRRDFIXUUSXRA-UHFFFAOYSA-N
- Smiles
- O=C1NC2=CC=CC=C2N1CCN3CCN(C4=CC=CC(C(F)(F)F)=C4)CC3
Flibanserin is a full agonist of the serotonin 5-HT1A receptor and an antagonist of 5-HT2A (Ki=1nm and 49nM, respectively). It also binds to dopamine D4 receptors with Ki values ranging from 4-24 nM, but demonstrates no affinity for the other 5-HT subtypes or other neurotransmitter receptors. Multifunctional serotonergic ligands like flibanserin that can enhance downstream release of dopamine and norepinephrine while concomitantly reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire, are being studied clinically for therapeutic potential to improve sexual functioning. Flibanserin was investigated as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin was also found to reduce L-DOPA-induced dyskinesia in a model of Parkinson?s Disease.
Additional information
| Synonyms | 1,3-Dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one, BIMT 17, BIMT 17BS |
|---|---|
| Purity | ≥98% (HPLC) |
| Appearance | White to beige powder |
| CAS-Number | 167933-07-5 |
| Molecular Formula | C20H21F3N4O |
| Molecular Weight | 390.40 |
| Identity | 1H-NMR |
| Solvents | DMSO (20mg/ml), DMF (20mg/ml), ethanol (10mg/ml) |
| Melting Point | 160.0°C-162.0°C |
| Smiles | O=C1NC2=CC=CC=C2N1CCN3CCN(C4=CC=CC(C(F)(F)F)=C4)CC3 |
| InChi Key | PPRRDFIXUUSXRA-UHFFFAOYSA-N |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Hazard statements | H301-H315-H319-H335 |
| Precautionary statements | P261-P301 + P310-P305 + P351 + P338 |
| GHS Symbol | GHS06 |
| Signal word | Danger |
| RIDADR | 2811 6.1 |
| Transportation | Packing Group III |
| References | (1) F. Borsini, et al., Naunyn Schmiedebergs Arch. Pharmacol. 352, 276 (1995), (2) F. Borsini, et al., Naunyn Schmiedebergs Arch. Pharmacol. 352, 283 (1995), (3) F. Borsini, et al., Psychopharmacology 134, 378 (1997), (4) A. Scandroglio, et al., Pharmacol. Res. 43, 179 (2001), (5) F. Borsini, et al., CNS Drug Rev. 8, 117 (2002) (Review), (6) R.W. Invernizzi, et al., Br. J. Pharmacol. 139, 1281 (2003), (7) H. Gelez, et al., J. Sex. Med. 10, 1231 (2013), (8) S.M. Stahl, CNS Spectr. 20, 1 (2015) (Review), (9) I. Dhanuka & J.A. Simon, Expert Opin. Pharmacother. 16, 2523 (2015) (Review) |
| Quantity | 5 mg, 25 mg, Bulk |
